Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease

Clinical Transplantation

Volumn 27, Issue 6, 2013, Pages 930-937

  Alam, Naheed ^a   Atenafu, Eshetu G ^a   Tse, Garwin ^a   Viswabandya, Auro ^a   Gupta, Vikas ^a   Kim, Dennis ^a   Lipton, Jeffrey H ^a   Messner, Hans A ^a   Kuruvilla, John ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Graft versus host disease; Hematopoietic cell transplant; Pentostatin

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PENTOSTATIN; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; LIVER; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REFRACTORY PERIOD; RELAPSE; SALVAGE THERAPY; SKIN; STEROID THERAPY; SURVIVAL TIME; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS REACTIVATION;

GRAFT-VERSUS-HOST DISEASE; HEMATOPOIETIC CELL TRANSPLANT; PENTOSTATIN;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PENTOSTATIN; PROGNOSIS; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84889098906     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12268     Document Type: Article

References (33)

1. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990: 75: 1024.
2. Jagasia M, Arora M, Flowers ME et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012: 119: 296.
3. Hahn T, McCarthy PL Jr, Zhang MJ et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008: 26: 5728.
4. Anasetti C, Beatty PG, Storb R et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990: 29: 79.
5. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995: 15: 663.
6. Weisdorf D, Hakke R, Blazar B et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991: 51: 1197.
7. Ludajic K, Balavarca Y, Bickeboller H et al. Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant 2009: 15: 1400.
8. Remberger M, Mattsson J, Hassan Z et al. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. Bone Marrow Transplant 2008: 41: 399.
9. Urbano-Ispizua A, Rozman C, Pimentel P et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34 + selected blood cells from HLA-identical siblings. Blood 2002: 100: 724.
10. Hagglund H, Bostrom L, Remberger M, Ljungman P, Nilsson B, Ringden O. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995: 16: 747.
11. MacMillan ML, Weisdorf DJ, Wagner JE et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002: 8: 387.
12. Westin JR, Saliba RM, De Lima M et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011: 2011: 601953.
13. Hings IM, Severson R, Filipovich AH et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994: 58: 437.
14. Schnitzler M, Hasskarl J, Egger M, Bertz H, Finke J. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009: 15: 910.
15. Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008: 14: 10.
16. Martinez C, Solano C, Ferra C, Sampol A, Valcarcel D, Perez-Simon JA. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant 2009: 15: 639.
17. Liu J, Wang HX, Duan LN et al. Antithymocyte globulin used for treatment of severe acute graft versus host disease after haploidentical bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007: 15: 816.
18. Motllo C, Ferra C, Lopez L, Morgades M, Batlle M, Ribera JM. Salvage treatment with infliximab of steroid-resistant graft-versus-host disease in allogeneic transplanted patients. Med Clin (Barc) 2011: 137: 115.
19. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007: 82: 45.
20. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004: 363: 1439.
21. Trzonkowski P, Bieniaszewska M, Juscinska J et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127- T regulatory cells. Clin Immunol 2009: 133: 22.
22. Alousi AM, Weisdorf DJ, Logan BR et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009: 114: 511.
23. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995: 15: 825.
24. Rowlings PA, Przepiorka D, Klein JP et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997: 97: 855.
25. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002: 8: 155.
26. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991: 77: 1821.
27. Roy J, McGlave PB, Filipovich AH et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992: 10: 77.
28. Benito AI, Furlong T, Martin PJ et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001: 72: 1924.
29. Schmitt T, Luft T, Hegenbart U, Tran TH, Ho AD, Dreger P. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant 2011: 46: 580.
30. Bolanos-Meade J, Jacobsohn DA, Margolis J et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005: 23: 2661.
31. Klein SA, Bug G, Mousset S, Hofmann WK, Hoelzer D, Martin H. Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin. Br J Haematol 2011: 154: 143.
32. Pidala J, Kim J, Roman-Diaz J et al. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant 2010: 15: 21.
33. MacMillan ML, Weisdorf DJ, Davies SM et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002: 8: 40.